Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

In patients with high comorbidity burden that receive EVT for MCA medium-vessel occlusion there are worse clinical outcomes.

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.

Machine learning models may be able to identify women with severe subjective cognitive decline (SCD) during the menopause transition.

Underweight pregnancy was associated with lower risk for postpartum hemorrhage but higher risks for adverse neonatal outcomes.

Increased intermuscular fat is associated with coronary microvascular dysfunction (CMD) and adverse cardiovascular outcomes.

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

President Donald Trump's administration has placed a freeze on information being released from government health agencies.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Childhood BMI trends — specifically moderate BMI and high BMI variability — were associated with high cortisol concentrations at 17 years of age.